Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
21.72
+0.07 (0.32%)
Mar 31, 2025, 3:37 PM EDT - Market open
AAPG Revenue
In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M CNY with 341.77% growth. Ascentage Pharma Group International had revenue of 156.90M in the half year ending December 31, 2024, with 37.70% growth.
Revenue (ttm)
980.65M CNY
Revenue Growth
+341.77%
P/S Ratio
13.88
Revenue / Employee
1,682,075 CNY
Employees
583
Market Cap
1.87B undefined
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AAPG News
- 4 days ago - Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan - Benzinga
- 5 days ago - Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 19 days ago - Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 - GlobeNewsWire
- 25 days ago - Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) - GlobeNewsWire
- 7 weeks ago - Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares - GlobeNewsWire
- 2 months ago - Ascentage Pharma Announces Closing of U.S. Initial Public Offering - GlobeNewsWire
- 2 months ago - Ascentage Pharma Announces Pricing of U.S. Initial Public Offering - GlobeNewsWire
- 3 months ago - Ascentage Pharma Group International IPO Registration Document (F-1) - SEC